Hui, Lucy <br/><br/>
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.  [electronic resource] 

 -  Cancer  Oct 2017 
 - 3763-3771 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.30818  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Autografts<br/>Brentuximab Vedotin<br/>Consolidation Chemotherapy--economics<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Health Care Costs<br/>Hematopoietic Stem Cell Transplantation<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--therapeutic use<br/>Markov Chains<br/>Middle Aged<br/>Quality of Life<br/>Quality-Adjusted Life Years